2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0415
    Trigonelline chloride 6138-41-6 99.88%
    Trigonelline chloride is an alkaloid with potential antidiabetic activity that can be isolated from Trigonella foenum-graecum L or Leonurus artemisia. Trigonelline chloride is a potent Nrf2 inhibitor that blocks Nrf2-dependent proteasome activity, thereby enhancing apoptosis in pancreatic cancer cells. Trigonelline chloride also has anti-HSV-1, antibacterial, and antifungal activity, and induces ferroptosis.
    Trigonelline chloride
  • HY-N0814
    Phytic acid (50% w/w in water) 83-86-3 98.13%
    Phytic acid (myo-Inositol; hexakis dihydrogen phosphate; Inositol hexaphosphate) is an orally active compound. Phytic acid can be derived from the seeds of legumes. Phytic acid is a [PO4]3- storage depot and precursor for other inositol phosphates and pyrophosphates. Phytic acid attenuates Aβ oligomers and upregulates autophagy protein. Phytic acid can be used in cardiovascular disease, metabolic disease, nervous system disease and cancer research.
    Phytic acid (50% w/w in water)
  • HY-N1499
    Nystose 13133-07-8 ≥98.0%
    Nystose is a tetrasaccharide with two fructose molecules linked via beta (1→2) bonds to the fructosyl moiety of sucrose. Nystose exhibits prebiotic, immunomodulatory, and metabolism regulating activities. Nystose promotes the bone mineralization by activating the Wnt/β-catenin signaling pathway.
    Nystose
  • HY-100793
    SR12813 126411-39-0 99.84%
    SR12813 (GW 485801) is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, with an IC50 value of 0.85 μM. SR12813 is also an efficient agonist of human pregnane X receptor (hPXR). SR12813 can strongly bind to hPXR but not to mouse PXR (mPXR).
    SR12813
  • HY-101906
    DC260126 346692-04-4 99.57%
    DC260126 is a potent antagonist of GPR40 (FFAR1). DC260126 dose-dependently inhibits GPR40-mediated Ca2+ elevations stimulated by linoleic acid, oleic acid, palmitoleic acid and lauric acid (IC50: 6.28, 5.96, 7.07, 4.58 μM, respectively). DC260126 could protect MIN6 β cells from palmitate-induced ER stress and apoptosis.
    DC260126
  • HY-104050
    M-31850 281224-40-6 99.79%
    M-31850 is a potent, selective and competitive β-hexosaminidase (Hex) inhibitor with IC50s of 6.0 μM and 3.1 μM for human HexA and human HexB, respectively. M-31850 also competitively inhibits β-N-acetyl-D-hexosaminidase OfHex2 with a Ki of 2.5 μM.
    M-31850
  • HY-107916
    Thyrotropin 9002-71-5
    Thyrotropin (TSH, Pretiron) is a thyroid-stimulating hormone produced by thyrotrope cells in the anterior pituitary gland. Thyrotropin regulates the endocrine function of the thyroid. Thyrotropin induces transcriptional regulation of TH-gatekeeper genes in tanycytes through the Tshr/Gαq/PKC pathway. Thyrotropin prevents Apoptosis. Thyrotropin has an association of low levels with increased bone remodeling, reduced bone mass and a high fracture risk in mice. Thyrotropin is promising for research of skeletal remodeling, hyperthyroidism.
    Thyrotropin
  • HY-114360
    Taurohyodeoxycholic acid 2958-04-5 99.73%
    Taurohyodeoxycholic acid is an orally active 6 alpha-hydroxylated bile acid. Taurohyodeoxycholic acid decreases colonic MPO activity, TNF-α, lL-6 serum levels and the expression of COX-2. Taurohyodeoxycholic acid alleviates trinitrobenzene sulfonic acid induced ulcerative colitis via regulating Th1/Th2 and Th17/Treg cells balance. Taurohyodeoxycholic acid ameliorates high-fat diet-induced nonalcoholic fatty liver disease in mice. Taurohyodeoxycholic acid prevents Taurochenodeoxycholic acid (HY-N2027)-induced hepatotoxicity in bile fistula rats. Taurohyodeoxycholic acid can be used for the study of nonalcoholic fatty liver disease (NAFLD), colitis and biliary fistula.
    Taurohyodeoxycholic acid
  • HY-119283
    CAY10499 359714-55-9 99.58%
    CAY10499 (MAGL-IN-5) is a non-selective lipase inhibitor with IC50 values of 144 nM and 14 nM for monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), respectively. Additionally, CAY10499 exhibits anti-inflammatory and antiviral activities.
    CAY10499
  • HY-124410
    Mitoquinol 845959-55-9 98.00%
    Mitoquinol is an orally active mitochondria-targeted antioxidant. Mitoquinol can regulate mitochondrial respiration and oxidation. Mitoquinol inhibits ROS production, and improves phagocytosis and glycolysis in ethanol-exposed macrophages via the HIF-1α-PFKP axis. Additionally, Mitoquinol can partially alleviate heat stress-induced decreases in growth performance, inflammatory responses, and metabolic disorders in pigs.
    Mitoquinol
  • HY-126358
    Acetylcarnitine 14992-62-2 98.0%
    Acetylcarnitine is a CNS-penetrant endogenous metabolite. Acetylcarnitine shuttling links mitochondrial metabolism to histone acetylation and lipogenesis. Acetylcarnitine attenuates oxidative stress and neuroinflammation. Acetylcarnitine can be used for fatigue-associated diseases research. Acetylcarnitine can be used as a candidate diagnostic and prognostic biomarker of hepatocellular carcinoma.
    Acetylcarnitine
  • HY-150105
    Icovamenib 2448172-22-1 98.96%
    Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes.
    Icovamenib
  • HY-N0390S9
    L-Glutamine-15N-1 59681-32-2 ≥98.0%
    L-Glutamine-15N-1 is the 15N-labeled L-Glutamine (HY-N0390). L-Glutamine is an orally active nutritional agent and cellular metabolism regulator. L-Glutamine is taken up in a Na+-dependent manner and targets multiple key molecules including glutaminase, mTORC1, NF-κB, STAT-3 and HIF-1α. L-Glutamine enhances glutaminolytic catabolism, drives the conversion of glutamate to α-ketoglutarate, thereby regulating gene expression, integrating metabolic signals, mediating glutamine flux and maintaining redox homeostasis. L-Glutamine also promotes cell proliferation, osteogenic differentiation and fracture healing, exerts neuroprotective and cardioprotective effects, and inhibits osteoarthritis. L-Glutamine can be applied to research related to osteoporosis, osteoarthritis, ischemic stroke and acute cantharidin-induced cardiotoxicity.
    L-Glutamine-15N-1
  • HY-W021448
    Glycocyamine 352-97-6
    Glycocyamine (Guanidinoacetic acid) is a direct precursor of creatine and an orally active energy metabolism regulator and myogenic differentiation inducer. Glycocyamine can activate the Akt/mTOR/S6K signaling pathway via miR-133a-3p and miR-1a-3p, and stimulate the mRNA expression of myogenic differentiation factor 1 (MyoD) and myopoietin (MyoG). Glycocyamine can increase muscle creatine concentration and maintain ATP homeostasis through the creatine phosphate/creatine kinase system. Glycocyamine can be used in research on feed additives for poultry farming.
    Glycocyamine
  • HY-B0240R
    Disulfiram (Standard) 97-77-8 99.54%
    Disulfiram (Standard) is the analytical standard of Disulfiram. This product is intended for research and analytical applications. Disulfiram (Tetraethylthiuram disulfide) is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram inhibits gasdermin D (GSDMD) pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Disulfiram + Cu2+ increases intracellular ROS levels triggering apoptosis of ovarian cancer stem cells[1-6].
    Disulfiram (Standard)
  • HY-B0442
    Vardenafil 224785-90-4 99.81%
    Vardenafil is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4. Vardenafil competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Vardenafil can be used for the research of erectile dysfunction, hepatitis, diabetes[1]-[6].
    Vardenafil
  • HY-13005
    Fagomine 53185-12-9 99.24%
    Fagomine is a mild glycosidase inhibitor. The Ki of the iminosugar Fagomine is 4.8 μM, 39 μM, and 70 μM for Amyloglucosidase (A.niger), β-Glucosidase (bovine), and Isomaltase (yeast), respectively.
    Fagomine
  • HY-15849
    LP-533401 945976-43-2 99.15%
    LP-533401 is a Tryptophan hydroxylase 1 inhibitor that regulates serotonin production in the gut.
    LP-533401
  • HY-19796
    Icomidocholic acid 246529-22-6 ≥99.0%
    Icomidocholic acid (Aramchol) is a lipid molecule synthesized from cholic acid and arachidic acid. Icomidocholic acid is an orally active SCD1 inhibitor and cholesterol solubilizer with antifibrotic effects. Icomidocholic acid can reduce liver fat content, dissolve cholesterol crystals and prevent gallstone formation. Icomidocholic acid can be used in the study of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
    Icomidocholic acid
  • HY-N2118
    Bilobetin 521-32-4 99.71%
    Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity.
    Bilobetin
Cat. No. Product Name / Synonyms Application Reactivity